Social Anxiety Disorder Clinical Trial
— SAD-Med-SohOfficial title:
Social Anxiety Disorder in Medical Students in Sohag University
| NCT number | NCT05336552 |
| Other study ID # | Soh-Med-22-04-13 |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | May 23, 2022 |
| Est. completion date | June 2023 |
The study will be done in Sohag University to assess the prevalence and associated factors of Social Anxiety Disorder among undergraduate medical students .
| Status | Recruiting |
| Enrollment | 350 |
| Est. completion date | June 2023 |
| Est. primary completion date | May 2023 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 25 Years |
| Eligibility | Inclusion Criteria: - Medical undergraduate students who are still studying for Bachelor of Medicine and Bachelor of Surgery ( M.B.B.Ch ) . Exclusion Criteria: - students who will refuse to participate in this study . |
| Country | Name | City | State |
|---|---|---|---|
| Egypt | Sohag university | Sohag |
| Lead Sponsor | Collaborator |
|---|---|
| Sohag University |
Egypt,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Social Phobia Inventory ( SPIN ) questionnaire | Social Phobia Inventory ( SPIN ) questionnaire which is consisted of 17 items. The answers of each item ranged from 0 ( Not at all ) to 4 ( Extremely ).
The total score will be calculated to determine the severity of the problem as the following: - less than or equal 20 points means no disease, 21-30 means mild, 31-40 means moderate, 41-50 means severe , 51 or more means very severe. |
It will be measured after completion of the study , approximately in May 2023. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06274112 -
Using TMS to Understand Neural Processes of Social Motivation
|
N/A | |
| Completed |
NCT02554929 -
Treatment of Social Anxiety Disorder and Selective Mutism
|
N/A | |
| Completed |
NCT00684541 -
Interpretation Modification Program for Social Phobia
|
N/A | |
| Completed |
NCT00684320 -
Attention Disengagement Training for Social Phobia
|
N/A | |
| Completed |
NCT03247075 -
Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT
|
N/A | |
| Completed |
NCT02811458 -
Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders
|
N/A | |
| Withdrawn |
NCT04622930 -
Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)
|
N/A | |
| Active, not recruiting |
NCT05018312 -
Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety
|
N/A | |
| Active, not recruiting |
NCT05124639 -
Clinical Trial of a Group Self-management Support Program for Anxiety Disorders
|
N/A | |
| Completed |
NCT05858294 -
The Safety, Acceptability and Efficacy of Alena
|
N/A | |
| Active, not recruiting |
NCT05600114 -
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
|
Phase 2 | |
| Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
| Not yet recruiting |
NCT02924610 -
Brief Intervention to Reduce Fear
|
Phase 4 | |
| Active, not recruiting |
NCT02592564 -
Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder
|
N/A | |
| Recruiting |
NCT02305537 -
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
|
N/A | |
| Terminated |
NCT03764644 -
Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders
|
N/A | |
| Unknown status |
NCT01712321 -
Study of Vilazodone to Treat Social Anxiety Disorder
|
N/A | |
| Completed |
NCT01320800 -
CBT for Social Anxiety Disorder Delivered by School Counselors
|
Phase 2 | |
| Completed |
NCT00485888 -
Flushing in Social Anxiety Disorder on Cipralex
|
Phase 2 | |
| Completed |
NCT00773162 -
Flushing in Social Anxiety Disorder on Seroquel
|
Phase 3 |